Skip to main content
Log in

Bioavailability of Orally Administered Micronised Fluticasone Propionate

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to determine the absolute oral bioavailability of fluticasone propionate (FP) in healthy volunteers.

Methods

A 3-period incomplete block crossover design was used. On separate occasions, 21 male volunteers received a single 250μg intravenous dose of FP (n = 21) and twice daily oral doses of either micronised FP 0.1mg (n = 9), 1mg (n = 12), 10mg (n = 11) or placebo (n = 9) for 4 days.

Results

FP was not measurable in the plasma after twice daily oral administration of a 0. 1mg dose. FP concentrations just above the limit of quantification could be measured in only 5 volunteers, and only at some time points, after administration of FP 1mg twice daily. At a dose of 10mg twice daily the absolute oral bioavailability of the drug was <1% when a liquid chromatography-mass spectrometry assay was used to assess plasma concentrations. Only oral doses of FP 10mg twice daily, 10 times greater than the recommended maximum inhaled dose, produced any detectable change in urinary cortisol excretion.

Conclusion

The results of this study confirm that oral absorption of FP into the systemic circulation is negligible. The swallowed portion of an inhaled dose of FP is unlikely to increase the systemic exposure to the drug, thus decreasing the likelihood of adverse systemic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Table II
Fig. 4

Similar content being viewed by others

References

  1. Ventresca GP, Mackie AE, Moss JA, et al. Absorption of oral fluticasone propionate in healthy subjects. Am J Respir Crit Care Med 1994; 149: A214.

    Google Scholar 

  2. Mackie AE, Falcoz C, McDowall JE, et al. Phannacokinetics of fluticasone propionate inhaled from the Diskhaler® and the Diskus® powder devices in healthy subjects. Br J Clin Pharmacol 1997; 43: 540P–1P.

    Google Scholar 

  3. Bain BM, Harrison G, Jenkins KD, et al. A sensitive radioim-munoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Anal 1993; 11: 557–61.

    Article  PubMed  CAS  Google Scholar 

  4. Jones AE, Callejas S, Sadra P, et al. The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC-MS. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics; 1997 Jun 1–5; Palm Springs, CA: 560.

  5. Rowland M, Tozer TN, editors. Clinical phannacokinetics: concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995.

    Google Scholar 

  6. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92(1): 95–104.

    Article  PubMed  CAS  Google Scholar 

  7. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332(13): 868–75.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christine Falcoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falcoz, C., Oliver, R., McDowall, J.E. et al. Bioavailability of Orally Administered Micronised Fluticasone Propionate. Clin Pharmacokinet 39 (Suppl 1), 9–15 (2000). https://doi.org/10.2165/00003088-200039001-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200039001-00002

Keywords

Navigation